Results 311 to 320 of about 137,192 (357)
Synergistic drug interactions of the histone deacetylase inhibitor givinostat (ITF2357) in CRLF2-rearranged pediatric B-cell precursor acute lymphoblastic leukemia identified by high-throughput drug screening. [PDF]
HeliyonOikonomou A +13 more
europepmc +1 more source
Effect of histone deacetylase and proteasome inhibitors in glioma models
Luciana; id_orcid 0000-0002-2306-7959 Costa Furtado +2 more
openalex +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Histone Deacetylase Inhibitors
ChemInform, 2003AbstractFor Abstract see ChemInform Abstract in Full Text.
Thomas A, Miller +2 more
openaire +2 more sources
Prospects: Histone deacetylase inhibitors
Journal of Cellular Biochemistry, 2005AbstractHistone deacetylase (HDAC), inhibitors represent a new class of targeted anti‐cancer agents. Several of these compounds are in clinical trials with significant activity against a spectrum of both hematologic and solid tumors at doses that are well tolerated by the patients.
Milos, Dokmanovic, Paul A, Marks
openaire +2 more sources
Histone deacetylase inhibitors
European Journal of Medicinal Chemistry, 2005AbstractFor Abstract see ChemInform Abstract in Full Text.
openaire +4 more sources
Selective Histone Deacetylase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry, 2012Histone deacetylases (HDACs) are a family of conserved metalloproteases which play a key role in the development of cancer. They can be divided into 18 subtypes according to their structural diversity. Histone deacetylase inhibitors are considered as potential anti-cancer agents and a lot of pan-HDAC inhibitors have entered clinical trials.
Huili, Pan, Jiangying, Cao, Wenfang, Xu
openaire +2 more sources
Histone Deacetylase Inhibitors
2004The base sequence of DNA provides the genetic code for proteins. The regulation of expression or suppression of gene transcription is largely determined by the structure of the chromatin--referred to as epigenetic gene regulation (Agalioti et al., 2002; Jenuwein and Allis, 2001; Richards and Elgin, 2002; Spotswood and Turner, 2002; Zhang and Reinberg ...
Paul A, Marks +3 more
openaire +2 more sources
Histone Deacetylase Inhibitors
2021Histone Deacetylase Inhibitors (HDACi) inhibits deacetylases of histones and nonhistones. As such it has potential widespread biological effects. However, cancer cells are preferentially affected than normal cells making it a useful targeted therapy in cancer.
Opelo Sefhore, Silvia CW Ling
openaire +1 more source
Histone deacetylase inhibitors
Expert Opinion on Therapeutic Patents, 2007Sustained efforts towards identifying novel histone deacetylase (HDAC) inhibitors as suitable therapies for the treatment of cancer and other human diseases has been a goal for the pharmaceutical industry during the last decade. In the second half of 2006 these efforts culminated in the FDA granting approval for the first HDAC inhibitor ...
Steve Price, Hazel J Dyke
openaire +1 more source
Histone deacetylase inhibitor based prodrugs
European Journal of Medicinal Chemistry, 2020Histone deacetylases (HDACs) are a family of enzymes which play important roles in the development and progression of cancers. Inhibition of HDACs has been widely studied as a therapeutic strategy in the discovery of anticancer drugs. HDAC inhibitors (HDACIs) have exhibited potency against a variety of cancer types, and four of them have been approved ...
Wenli Fan +5 more
openaire +2 more sources